ANNOUNCING THE LAUNCH OF JDS THERAPEUTICS, LLC,
FOR IMMEDIATE RELEASE: ANNOUNCING THE LAUNCH OF JDS THERAPEUTICS, LLC, LED BY PHILLIP AND MICHAEL SATOW
JDS Therapeutics, LLC will market assets acquired from purchase of Nutrition 21, Inc.
PURCHASE, NY, November 28, 2011 – JDS Therapeutics, LLC, announced effective immediately it will market proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals. JDS Therapeutics acquired assets from the purchase of Nutrition 21, Inc.
The assets were acquired in November 2011 by an investment group led by Phillip Satow and Michael Satow, and are now part of JDS Therapeutics, LLC. Michael Satow serves as President and Chief Executive Officer and Phillip Satow as Chairman of the Board. Phillip and Michael together have almost 50 years of healthcare experience. Most recently, they founded and built JDS Pharmaceuticals, LLC, a specialty pharmaceutical company focused on the psychiatric and women’s health markets. JDS Pharmaceuticals was successfully sold to Noven Pharmaceuticals in 2007 for $125 million.
Michael Satow commented, “We are very excited about the launch of JDS Therapeutics. As CEO, I am committing the Company to continuing the highest standards of quality and customer service. We intend to invest in and grow the business as well expand the Company’s range of offerings.” Phillip M. Satow, Chief Executive Officer and co-founder of JDS, added: “We have assembled a highly-experienced management team to help us rapidly achieve the vision we
have for JDS.”
Prior to JDS, Phillip Satow was Executive Vice President of Forest Laboratories, Inc. and President of Forest Pharmaceuticals as well as a member of the Forest board of directors. Phillip also served in senior positions at Pfizer and Carter Wallace. He has served on the boards of directors of public companies, including Forest Laboratories, Inc., Crucell Inc., Eyetech, Inc., and Noven. Prior to JDS, Michael founded and/or served as CEO of several venture backed companies as well as practicing as an attorney for five years. Michael currently sits on several private companies and non-profit boards.
Michael Satow began his career as an attorney in private practice and as an enforcement lawyer at the SEC. In 1997, after five years of practicing law, Michael founded and served as CEO of MarketXT, the first retail after-hour stock market, with backing from Morgan Stanley and Salomon Smith Barney. For his work with MarketXT, US News & World Report named Michael one of the Top 10 American Innovators. He sold this venture in 2000 for $100 million. From 2000 to 2002, he served as CEO of Mirror Worlds Technologies, a knowledge management software company and the makers of Scopeware. He currently serves on the board of directors of Houseparty, Inc. and Skymarker LLC. In addition, Michael serves on the boards of The Jed Foundation, a leading charity focused on protecting the mental health of students across the country, and My Sister’s Place, Westchester’s primary domestic violence agency. Michael received a BA from Columbia College and a JD from the Georgetown University Law Center.
About JDS Therapeutics:
JDS Therapeutics markets proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals. JDS is focused on providing patients with scientifically backed, natural approaches to meeting their healthcare needs. JDS Therapeutics owns more than 100 issued patents worldwide involving clinically active natural compounds. JDS was founded in 2011, by Phillip and Michael Satow, a father and son team whose previous company, JDS Pharmaceuticals was sold in 2007 to Noven Pharmaceuticals for $125 million.
For more information, please contact us.